Biology

Colorectal cancer

Clostridium difficile

Fecal bacteriotherapy

Transplantation

Cirrhosis

Immunology

Microbiome

Bioinformatics

Rifaximin

Colonoscopy

Hepatic encephalopathy

Antibiotics

Microbiology

Internal medicine

Feces

Gut flora

Medicine

Ulcerative colitis

Gastroenterology

Dysbiosis

Irritable bowel syndrome

Disease

Cancer

Clostridioides

Annual Review of Medicine

Fecal microbiota transplantation (FMT) is a well-established treatment for recurrent Clostridioides difficile infection. FMT has become a more readily available and useful new treatment option as a result of stool banks. The current state of knowledge indicates that dysbiosis of the gut microbiota is implicated in several disorders in addition to C. difficile infection. Randomized controlled studies have shown FMT to be somewhat effective in treating ulcerative colitis, irritable bowel syndrome, and hepatic encephalopathy. In addition, FMT has been beneficial in treating several other conditions, such as the eradication of multidrug-resistant organisms and graft-versus-host disease. We expect that FMT will soon be implemented as a treatment strategy for several new indications, although further studies are needed.

Clinical Application and Potential of Fecal Microbiota Transplantation